Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Chief Scientific Officer | December 15, 2020 | December 17, 2020 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date December 15, 2020 · Filed December 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-04-01 | Direct | 8,912 |
Reported balance
After 2020-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-15 · Grant · Acquired 8,912 · Balance 8,912 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2: 3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-07-20 | Direct | 10,832 |
Reported balance
After 2020-12-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-15 · Grant · Acquired 10,832 · Balance 10,832 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3: 4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.80 · Expires 2030-09-29 | Direct | 5,717 |
Reported balance
After 2020-12-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-15 · Grant · Acquired 5,717 · Balance 5,717 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4: 2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.
F2: 3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F3: 4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F4: 2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
PROKIDNEY CORP.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28 | Direct | 135,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eidos Therapeutics, Inc.
Report date January 26, 2021 · Filed January 29, 2021
Section 16 reporting ended · disclosed 2021-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-01-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-10-27 · Gift · Disposed 3,000 · Balance 303,525 Row 2 · 2021-01-26 · Other · Disposed 303,525 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2028-11-05 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-26 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock.
F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2018 Filed May 28, 2019 20:01 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 1,081 | $12.01 | $12,982.81 |
DisclosureSEC source: 0000899243-19-014838 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,312 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| November 05, 2018 Filed Nov 8, 2018 00:06 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0000899243-18-028483 · doc4.xml · derivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-11-05 F1 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 60,000 stock options (the "Grant") on November 5, 2018. The shares subject to the Grant shall vest as follows: one quarter of the shares shall vest on November 5, 2019 and the remaining unvested shares shall vest ratably over the following 36 months, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.